Home - IGM Biosciences
Jan 9, 2025 · IGM Biosciences is pioneering a new class of antibody medicines for the treatment of autoimmune and inflammatory diseases. Building upon the greater binding power provided …
About Us - IGM Biosciences
Through tenacity, creativity, courage, and a decade of dedicated research, we have created unique IgM antibodies with high selectivity, affinity, and avidity that may redefine what is …
Pipeline & Programs - IGM Biosciences
Our ability to develop engineered IgM antibodies against various targets allows for a broad and differentiated product pipeline. We have robust research and pre-clinical development plans …
1. Introduction to Immunoglobulin M (IgM) During humoral immune responses, immunoglobulins of the IgM, IgD, IgG, IgA, and IgE isotypes may be produced, each expressing a unique …
Cookies Notice - IGM Biosciences
Cookies in no way give IGM access to your device or any information other than the data you choose to share with IGM. These cookies help to improve the functioning of IGM’s website and …
• IGM-2323 is an IgM-based bispecific that uses an anti-CD20 IgM to provide high avidity binding to CD20, an scFv fused to the N-terminus of J-chain to provide monovalent engagement of …
IGM Platform - IGM Biosciences
Using our proprietary IgM platform, we are committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases.
Imvotamab (IGM-2323) - IGM Biosciences
IGM-2323 is an IgM-based CD20 x CD3 bispecific antibody T-cell engager for the treatment of B cell Non-Hodgkin’s lymphoma (NHL.)
Presentations 2024 - IGM Biosciences
Therapeutic Potential of Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, for the Treatment of Refractory Autoimmune Disease Patients
Management - IGM Biosciences
Senior Vice President, Corporate Controller and Principal Accounting Officer All content © IGM Biosciences, Inc. Privacy Policy Cookies Notice Terms of Use info ...